Evidence map›Paper›PMID 30096310›Full record

ReviewCell2018

Microbiome: Focus on Causation and Mechanism.

Michael A Fischbach

Abstract readReview
In one paragraph

Review in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Bacterial-derived cyclic lipopeptides suppress dauer arrest inbioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michael A FischbachDepartment of Bioengineering and ChEM-H, Stanford University and Chan Zuckerberg Biohub, Stanford, CA 94305, USA. Electronic address: fischbach@fischbachgroup.org.

Funding

Dietary and Microbial Reprogramming of Intestinal Microbiota-Produced MetabolitesR01DK101674 · NIDDK · STANFORD UNIVERSITY · PI FISCHBACH, MICHAEL ANDREW, MEYER, TIMOTHY W · 2014 to 2024
$6.5M
A complete map of the top 100 molecules from the gut microbiomeDP1DK113598 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FISCHBACH, MICHAEL ANDREW · 2016 to 2020
$5.5M
Antibiotics from nose and throat commensals that impact pathogen colonizationR01AI101018 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI FISCHBACH, MICHAEL ANDREW, LEMON, KATHERINE PAIGE · 2012 to 2021
$4.4M
Identification and characterization of natural products from the human microbiotaR01DK110174 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FISCHBACH, MICHAEL ANDREW · 2016 to 2019
$1.4M
NIAID NIH HHS R01 AI101018NIDDK NIH HHS DP1 DK113598NIDDK NIH HHS R01 DK101674NIDDK NIH HHS R01 DK110174
6 · The paper itself

Abstract

There is tremendous enthusiasm for the microbiome in academia and industry. This Perspective argues that in order to realize its potential, the field needs to focus on establishing causation and molecular mechanism with an emphasis on phenotypes that are large in magnitude, easy to measure, and unambiguously driven by the microbiota.

Indexed as

MicrobiotaBacterial InfectionsHumans

Identifiers

PMID30096310
PMCPMC6094951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.